Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20499600 | 0.90 | DRD2 (0.37) | DRD2DRD3HTR2AHTR1AHRH1 | |
| SCHEMBL1438338 | 0.76 | DRD2 (0.46) | DRD2DRD3 | |
| SCHEMBL444346 | 0.74 | DRD2 (0.43) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL7284535 | 0.74 | — | — | |
| SCHEMBL467080 | 0.74 | SMN1; SMN2 (0.35) | KCNH2 | |
| SCHEMBL1626963 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4536932 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL357358 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL8538844 | 0.73 | DRD2 (0.65) | DRD2DRD3HTR2AHTR1A | |
| SCHEMBL4437538 | 0.72 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761406-B | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-3778576-B1 | 2-CYANOPYRIMIDIN-4-YL CARBAMATE OR UREA DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | HANLIM PHARMACEUTICAL CO LTD (KR) | 2024-04-17 | — | — | EP | claimed |
| EP-4069693-B1 | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-20 | — | — | EP | claimed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | claimed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | claimed |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-02 | — | — | US | claimed |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | claimed |
| CN-113150025-B | Silicon-center chiral silica compound and preparation method thereof | 南方科技大学 | 2023-01-03 | — | — | CN | claimed |
| CN-114761406-A | Hydropyrido [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114599652-A | Hydropyrazino [1,2-d ] [1,4] diazepin compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20060009528-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2006-01-12 | — | — | US | claimed |
| EP-1539662-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2005037285-A1 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | CHIRON CORPORATION (US) | 2005-04-21 | — | — | US | claimed |
| WO-2004014825-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030232859-A1 | Cannabinoid receptor ligands | SCHERING CORPORATION | 2003-12-18 | — | — | US | claimed |
| EP-1368308-A1 | CANNABINOID RECEPTOR LIGANDS | Schering Corporation (US) | 2003-12-10 | — | — | EP | claimed |
| WO-2002062750-A9 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORP (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SCHERING CORPORATION | 2003-05-22 | — | — | US | claimed |
| WO-2002062750-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009528-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | DRD2 601/4885DRD3 757/4885HTR2A 372/4885 |
| US-20050085482-A1 | 2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase | RAF1, BRAF, ARAF | DRD2 2095/4885DRD3 3013/4885HTR2A 2953/4885 |
| US-20230022297-A1 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | TLR7, TLR9, TLR5 | DRD2 1892/4885DRD3 2400/4885HTR2A 108/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | DRD2 4349/4885DRD3 4702/4885HTR2A 2028/4885 |
| US-20030096844-A1 | Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity | SULT2A1, NFKBIA, SULT1A1 | DRD2 3772/4885DRD3 3928/4885HTR2A 3916/4885 |
| US-20030232859-A1 | Cannabinoid receptor ligands | CNR1, CNR2, GPR18 | DRD2 924/4885DRD3 951/4885HTR2A 756/4885 |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, HRH4, HRH2 | DRD2 209/4885DRD3 146/4885HTR2A 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.